ライフサイエンスコーパス: moderate to severe

1 ted venous contamination as absent, mild, or moderate to severe.

2 We compared peripheral blood from 32 moderate-to-severe AA adults with 43 moderate-to-severe

3 n children aged 6 to less than 12 years with moderate-to-severe AA.

4 history of smoking, use of pain modulators, moderate to severe abdominal pain, a severe gastroesopha

5 iotics still have a role in the treatment of moderate-to-severe acne, but only with a topical retinoi

6 Adult emergency department patients with moderate to severe acute distress (n = 120; 85% accident

7 cluded 416 patients aged 21 to 64 years with moderate to severe acute extremity pain enrolled from Ju

8 Therapy for moderate to severe acute food protein-induced enterocoli

9 Moderate to severe acute migraine attacks can be treated

10 Opioids are first-line drugs for moderate to severe acute pain and cancer pain.

11 dnisolone 1 mg/kg/day in patients with early moderate to severe acute respiratory distress syndrome (

12 We studied 778 patients with moderate to severe acute respiratory distress syndrome.

13 ine and after cyclosporine A treatment in 25 moderate to severe AD patients.

14 Sera from 20 subjects with moderate to severe AD, 10 subjects with CD, 12 subjects

15 We studied 27 children and 34 adults with moderate-to-severe AD (mean SCORAD score, 55 and 65, res

16 We studied 34 adults with moderate-to-severe AD (mean SCORAD score, 65), 24 patien

17 K high-throughput proteomic assay to analyze moderate-to-severe AD (n = 59) compared to psoriasis (n

18 Sera from 193 adult patients with moderate-to-severe AD (six area, six sign atopic dermati

19 Up to 50% of patients with moderate-to-severe AD in European populations have FLG-n

20 from 32 moderate-to-severe AA adults with 43 moderate-to-severe AD patients and 30 age-matched contro

21 olled multicenter study, adult patients with moderate-to-severe AD were educated by referring to a co

22 mmune and barrier responses in patients with moderate-to-severe AD, associating higher baseline sever

23 Three studies of patients with moderate-to-severe AD, including 4 to 6 months of daily/

24 ks in biopsy specimens from 15 patients with moderate-to-severe AD.

25 and severe ADL impairment and decreased for moderate-to-severe ADL impairment.

26 roved in early 2017 in the United States for moderate-to-severe adult AD.

27 . aureus populations from nine children with moderate to severe AE and 18 non-atopic children asympto

28 Moderate to severe airway obstruction was seen in 3.6%.

29 Patients (>/=12 years of age) with moderate to severe allergic asthma and who were being tr

30 events, such as hemorrhage (anticoagulants), moderate to severe allergic reactions (antibiotics), and

31 lacebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial

32 NO-AD) trial, community-living patients with moderate-to-severe Alzheimer's disease (who had been pre

33 +3), grouped (</= +1, none to mild; >/= +2, moderate to severe), and reported as unchanged from base

34 , mild; 2, mild to moderate; 3, moderate; 4, moderate to severe; and 5, severe.

35 vs 30.0%; HR, 1.52; 95% CI, 1.02-2.29), and moderate to severe aortic regurgitation (22.4% vs 14.7%;

36 Inherited aortopathies, moderate to severe aortic regurgitation, and severe aort

37 0.02), and lower core laboratory-adjudicated moderate-to-severe aortic insufficiency (4.2% versus 13.

38 decreases 28-day mortality of patients with moderate to severe ARDS compared with a conventional low

39 In patients with moderate to severe ARDS, a strategy with lung recruitmen

40 hrough April 25, 2017, enrolling adults with moderate to severe ARDS.

41 patients were randomized within 24 hours of moderate-to-severe ARDS onset to receive either intraven

42 ic bone marrow-derived MSCs in patients with moderate-to-severe ARDS.

43 he heterogeneous population of patients with moderate to severe AS.

44 rough July 2013, enrolling black adults with moderate to severe asthma in the United States.

45 nd epithelial brushings of 107 subjects with moderate to severe asthma were annotated by gene set var

46 hundred two children aged 5 to 17 years with moderate to severe asthma were enrolled in a 12-month ra

47 bstruction and radiological abnormalities in moderate to severe asthma.

48 nd a number of radiological abnormalities in moderate to severe asthma.

49 presenting to the emergency department with moderate to severe asthma.

50 Twenty-nine patients with moderate-to-severe asthma and 26 control subjects were e

51 We recruited patients with persistent, moderate-to-severe asthma and an elevated sputum eosinop

52 function and asthma control in patients with moderate-to-severe asthma and deserves further study for

53 s well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil c

54 We stratified patients with moderate-to-severe asthma based on clinicophysiologic pa

55 Self-management of moderate-to-severe asthma depends on the patient's abili

56 ith high airway mucosal CCL26 expression and moderate-to-severe asthma had Feno values (>/=35 ppb) an

57 te asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed.

58 pic," and "Late-onset asthma." Children with moderate-to-severe asthma were present in each cluster.

59 In some patients with moderate-to-severe asthma, particularly those with noneo

60 T1 consists of patients with well-controlled moderate-to-severe asthma, whereas cluster T2 is a group

61 st versus montelukast alone in patients with moderate-to-severe asthma.

62 ped, validated, and then read to adults with moderate-to-severe asthma.

63 Moderate-to-severe atherosclerosis was present in 445 (3

64 se 3 study (LIBERTY AD CHRONOS), adults with moderate-to-severe atopic dermatitis and inadequate resp

65 b improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent

66 al dose regimens of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately contro

67 substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable saf

68 with topical corticosteroids in adults with moderate-to-severe atopic dermatitis.

69 ents aged 4 years or older with a history of moderate to severe attacks were included.

70 s (SD 9.7) and 173 (68%) of 253 patients had moderate-to-severe baseline disease.

71 hil counts related to a higher prevalence of moderate-to-severe BHR than having normal Feno levels an

72 Moderate-to-severe BHR was defined as a cumulative dose

73 -IV-R binge-eating disorder criteria and had moderate to severe binge eating disorder (>/=3 binge-eat

74 ylate maintenance of efficacy in adults with moderate to severe binge-eating disorder.

75 mposite major adverse cardiovascular events, moderate to severe bleeding, and stent thrombosis.

76 In patients with moderate to severe bronchial hyperresponsiveness and nas

77 ivariable logistic regression analysis, only moderate to severe bronchial hyperresponsiveness and nas

78 among infants with a first episode of acute moderate to severe bronchiolitis who were admitted to th

79 (means-tested) national grant still reported moderate to severe burden.

80 Nighttime, daytime, and 24-h moderate-to-severe CAs were associated with increased ca

81 of less than 20/40 (P < .0001), presence of moderate to severe cataracts (P < .0001), advanced stage

82 placebo-controlled study of 119 adults with moderate to severe CD failed by treatment with tumor nec

83 The Amsler grid can be used to screen for moderate to severe central vision loss from glaucoma.

84 ned as the presence of any of the following: moderate to severe cerebral palsy, a cognitive score les

85 Cryptosporidium is a leading cause of moderate to severe childhood diarrhea in resource-poor s

86 use in populations with type 2 diabetes and moderate to severe chronic kidney disease (CKD), congest

87 n to decrease exacerbations in patients with moderate to severe chronic obstructive pulmonary disease

88 imary indication for mechanical ventilation; moderate to severe chronic obstructive pulmonary disease

89 ICANCE STATEMENT Neuropathic pain, a type of moderate to severe chronic pain resulting from nerve inj

90 1 comorbidity; and absence of heart failure, moderate-to-severe chronic obstructive pulmonary disease

91 Participants aged 18 years or older with moderate-to-severe chronic plaque psoriasis (body surfac

92 Adult outpatients with moderate-to-severe chronic plaque psoriasis were include

93 tolerated in the treatment of patients with moderate-to-severe chronic plaque psoriasis.

94 flammatory metabolic milieu in patients with moderate to severe CKD through a pilot, randomized, 2x2

95 s and inflammatory response in patients with moderate to severe CKD.

96 y Evaluation-27-defined no or minimal versus moderate-to-severe comorbidity adjusting for age, PC pro

97 is unlikely to prolong survival in men with moderate-to-severe comorbidity but may prolong survival

98 Audiometry was performed and revealed moderate to severe conductive hearing loss bilaterally,

99 uncontrolled (PR, 1.19; 95% CI, 1.05-1.35), moderate-to-severe controlled (PR, 1.33; 95% CI, 1.09-1.

100 ervices: mild controlled, mild uncontrolled, moderate-to-severe controlled, and moderate-to-severe un

101 double-blind study randomized patients with moderate to severe COPD (already on standard therapy) to

102 udy enrolled former and current smokers with moderate-to-severe COPD (n = 51).

103 in 1 s (FEV1) of lower than 50%, one or more moderate-to-severe COPD exacerbation in the previous 12

104 in 1 s (FEV1) of less than 50%, at least one moderate-to-severe COPD exacerbation in the previous 12

105 Secondary endpoints included moderate-to-severe COPD exacerbation rate over 52 weeks.

106 The primary endpoint was moderate-to-severe COPD exacerbation rate.

107 milast treatment added to current therapy in moderate-to-severe COPD with chronic bronchitis.

108 In stable patients with moderate-to-severe COPD, endogenous arginine production

109 rease the risk of pneumonia in patients with moderate-to-severe COPD.

110 In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatm

111 copic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with

112 s disease for at least 3 months, assessed as moderate-to-severe Crohn's disease at screening, defined

113 effective in relieving pain in patients with moderate to severe CRPS of 1 to 5 years' duration.

114 effective treatment option for patients with moderate-to-severe CSU symptoms and angioedema unrespons

115 nt therapeutic options for treating multiple moderate-to-severe cutaneous diseases.

116 A total of 41 eyes from 25 patients with moderate to severe DED were evaluated for the Esclera SC

117 Of children with moderate-to-severe definite RHD, 47.6% had echocardiogra

118 vation (percentage extent < 30%), and 22 had moderate to severe denervation (percentage extent > 30%,

119 .2 to 2.4]), and psychological problems (eg, moderate to severe depression according to the Patient H

120 Patients had chronic moderate to severe depression at baseline (the mean MADR

121 therapy, alongside CBT, for adolescents with moderate to severe depression who are attending routine

122 ession symptoms for patients with persistent moderate to severe depression, but functional outcomes a

123 pain, a severe gastroesophageal reflex, and moderate to severe depression.

124 a phase 2B randomized trial of patients with moderate to severe DG, relamorelin significantly reduced

125 hared sanitation access, as risk factors for moderate-to-severe diarrhea (MSD) in children less than

126 agent of amebiasis, as one of the causes of moderate-to-severe diarrhea in sub-Saharan Africa and So

127 GEMS was a study of moderate to severe diarrhoea in children younger than 5

128 cts most adolescents, and of those affected, moderate to severe disease occurs in 20%.

129 east 6 months before baseline, had currently moderate to severe disease, and were methotrexate treatm

130 placebos developed diarrhea, 7 experiencing moderate to severe disease.

131 or the management of eczema in children with moderate to severe disease.

132 ticosteroids are the treatment of choice for moderate to severe disease.

133 Almost 50% of patients had moderate-to-severe disease activity as reported by Urtic

134 code for psoriasis were classified as having moderate-to-severe disease if they had been prescribed p

135 (186,076 with mild psoriasis and 12,290 with moderate-to-severe disease) were included in the analysi

136 atment approach, especially in patients with moderate-to-severe disease.

137 lity of life, particularly for patients with moderate-to-severe disease.

138 Children aged 1 to 15 y with moderate to severe eczema were recruited from secondary

139 benefit over standard care in children with moderate to severe eczema.

140 36-43 weeks of gestational age, had signs of moderate to severe encephalopathy and moderately or seve

141 ophilic airway inflammation in patients with moderate-to-severe eosinophilic asthma.

142 Adjusted annual moderate-to-severe exacerbation frequencies were 0.41 fo

143 Moderate-to-severe exacerbation rates were 0.46 (95% CI

144 itment to the intestinal wall, especially in moderate to severe exacerbations of IBD.

145 Moderate to severe fatigue was recorded in eight (3%) pa

146 The association of rs1012068 with moderate to severe fibrosis was confirmed in an independ

147 rain natriuretic propeptide, as well as with moderate-to-severe fibrosis on myocardial biopsy and his

148 Seventy-one patients with moderate to severe FMR (mean 67.7 +/- 11.3 years of age,

149 of daily living (ADL) (defined as severe or moderate to severe) for adults aged 60 years or older (n

150 ek, phase 2B study of diabetic patients with moderate to severe gastroparesis symptoms (DG).

151 age 75 years [IQR 61-82]) had treatment for moderate-to-severe (grade 3+) or severe (grade 4+) mitra

152 4 had shorter donor ICU stay, lower rate of moderate-to-severe graft macrosteatosis (2.3% vs 8%), an

153 4 had shorter donor ICU stay, lower rate of moderate-to-severe graft macrosteatosis (2.3% vs 8%), an

154 This results in a moderate to severe growth phenotype in deletion mutants,

155 y OSA as none (0-4.9/h), mild (5-14.9/h), or moderate to severe (>/=15/h).

156 ety of the SQ HDM SLIT-tablet in adults with moderate-to-severe HDM-induced allergic rhinitis (AR).

157 European countries including 992 adults with moderate-to-severe HDM-induced AR despite treatment with

158 ms by which FVIII missense mutations lead to moderate to severe hemophilia A.

159 Patients with moderate to severe hidradenitis suppurativa failing adal

160 In patients with moderate-to-severe hypoxemia, the expired tidal volume a

161 n two consanguineous multiplex families with moderate to severe ID, epilepsy, and variable neuropsych

162 in approximately 35%-40% of individuals with moderate to severe ID.

163 or disruptions in body weight trajectory and moderate to severe illnesses.

164 2005, and then confirmed symptom timing and moderate-to-severe impact and severity of symptoms with

165 o radiologists rated venous contamination as moderate to severe in 64% (27 of 42) and 69% (29 of 42)

166 t in 85%, mucoid or mucopurulent in 90%, and moderate to severe in 86% of the subjects.

167 r very mild in the preclinical cases and was moderate to severe in end-stage corticobasal degeneratio

168 eous effect over standard treatment alone in moderate to severe infectious keratitis over a 30-day pe

169 Thirty eyes from 30 patients with moderate to severe infectious keratitis were randomized

170 truncating mutations in TBC1D23 who display moderate to severe intellectual disability and microceph

171 The clinical phenotype of KS includes moderate to severe intellectual disability with absent s

172 The core phenotype includes moderate to severe intellectual disability, and many ind

173 Prediction models for persistent pain of moderate to severe intensity at 1 year postoperatively w

174 s included tortuosity in all cases (91% were moderate to severe), irregular stenosis in 59%, smooth s

175 mal approach to managing patients with SIHD, moderate-to-severe ischemia, and symptoms that can be co

176 Children with moderate to severe latent RHD have poor outcomes.

177 s and estimated the efficacy of LAIV against moderate-to-severe LCI and other prespecified non-LCI cl

178 The efficacy of LAIV against vaccine-strain moderate-to-severe LCI was 56.7% (95% confidence interva

179 LAIV was efficacious against moderate-to-severe LCI.

180 t, 81 of the 141 participants (57%) reported moderate to severe levels of state anxiety.

181 r stay in intensive care, with 57% reporting moderate to severe levels.

182 valuating high-altitude travelers who report moderate to severe limitations in activities of daily li

183 Confocal microscopy showed moderate to severe loss of corneal endothelial cells in

184 ad bile duct loss on liver biopsy, which was moderate to severe (<50% of portal areas with bile ducts

185 MELD score significantly increased, whereas moderate-to-severe macrosteatosis and ischemia time decr

186 MELD score significantly increased, whereas moderate-to-severe macrosteatosis and ischemia time decr

187 ta from 71 adolescents and young adults with moderate to severe major depressive disorder, none of wh

188 y microglial activation, in the ACC during a moderate to severe major depressive episode.

189 Most people treated for moderate to severe MDD in Danish psychiatric hospitals d

190 jectories in a large sample of patients with moderate to severe MDD.

191 elow the mean for age and sex and results in moderate to severe mental deficiencies and decreased lif

192 Patients with moderate to severe mitral stenosis or mechanical heart v

193 Eight patients had recurrence of moderate-to-severe MR (4 simple, 4 complex), with a 5-ye

194 for the long-term, and significantly lowered moderate-to-severe MR recurrence.

195 S meningitis is an important risk factor for moderate to severe NDI, affecting around 1 in 5 survivor

196 low-up, including 18% (95% CI, 13%-22%) with moderate to severe NDI.

197 group vs 18% in the placebo group), or with moderate to severe neurodevelopmental impairment (7% in

198 D) and kernicterus has been used to describe moderate to severe neurologic dysfunction observed in ch

199 mains the standard of care for patients with moderate to severe neurological deficits who present wit

200 actions (antibiotics), and hypoglycemia with moderate to severe neurological effects (diabetes agents

201 ld nonproliferative DR (NPDR; n = 32 [38%]), moderate-to-severe NPDR (n = 31 [37%]), or proliferative

202 positive airway pressure in asthmatics with moderate to severe obstructive sleep apnea syndrome.

203 impact of SDB, particularly in children with moderate to severe obstructive sleep apnea, and also tha

204 Cancer-induced bone pain is characterized by moderate to severe ongoing pain that commonly requires t

205 nhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy.

206 d in 10 normal subjects and 10 patients with moderate-to-severe or severe organic mitral regurgitatio

207 toms (moderate: OR, 0.99; 95% CI, 0.82-1.21; moderate to severe: OR, 1.46; 95% CI, 1.19-1.80; and sev

208 rial in 307 consecutive women diagnosed with moderate to severe OSA (apnea-hypopnea index, >/=15) in

209 tes is 10% for mild OSA and 3.8% to 6.5% for moderate to severe OSA; current prevalence may be higher

210 ferences were found between the mild OSA and moderate-to-severe OSA groups.

211 Relative to subjects without apnea, moderate-to-severe OSA was significantly associated with

212 It involved 47 adults with DSM-V moderate-to-severe OUD.

213 r surgery is a well-recognized problem, with moderate to severe pain affecting 15% to 20% of women at

214 s are the most widely prescribed therapy for moderate to severe pain clinically, they have been noted

215 Current treatment of moderate to severe pain in SCD is mostly reliant upon op

216 rge (54.3%) closely matches the incidence of moderate to severe pain in trauma patients, indicating a

217 d adverse effects to analgesic treatment for moderate to severe pain that interfered with functional

218 pioid abuse and dependence among adults with moderate to severe pain, careful monitoring and consider

219 sts are the mainstay analgesics for treating moderate to severe pain.

220 ker implantation, major vascular damage, and moderate-to-severe paravalvular regurgitation were signi

221 (OR, 0.36; 95% CI, 0.17-0.75; P < .001) and moderate-to-severe PEP by 80% (OR, 0.20; 95% CI, 0.07-0.

222 ence interval [CI], 0.24-0.51; P < .001) and moderate-to-severe PEP by 83% (OR, 0.17; 95% CI, 0.09-0.

223 s who received rectal indomethacin developed moderate-to-severe PEP vs 4.32% who did not receive rect

224 Moderate to severe periodontitis was noted in 98% of pat

225 d against a reference standard of severe and moderate-to-severe periodontitis based on full-mouth exa

226 Fifty-five adults with moderate-to-severe periodontitis were enrolled in a rand

227 One hundred eighty-four patients with moderate-to-severe periodontitis were randomly allocated

228 The outcome variable was moderate to severe persistent pain at 1 year from surger

229 Results Moderate to severe persistent pain occurred in 13.5%, 13

230 ith no or minimal symptoms and medication or moderate to severe persistent) and atopic status (determ

231 ic therapeutic approved for the treatment of moderate-to-severe persistent allergic asthma (AA) that

232 withdrawal study that included subjects with moderate-to-severe persistent asthma receiving long-term

233 f subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis.

234 rosis factor therapies, for the treatment of moderate-to-severe plaque psoriasis.

235 d interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis.

236 Moderate-to-severe post-thrombotic syndrome occurred in

237 mild disease, and common marmosets exhibited moderate to severe, potentially lethal, disease.

238 spitalized during the first year of life for moderate to severe protein-energy malnutrition, then fol

239 re AD, 10 subjects with CD, 12 subjects with moderate to severe PS, 10 subjects with both AD and CD,

240 Kim et al. examined lesions from mild and moderate to severe psoriasis and found that differences

241 ronary artery calcium score in patients with moderate to severe psoriasis compared with patients with

242 Children with moderate to severe psoriasis had a higher mean WtHR than

243 Three of 15 children with moderate to severe psoriasis had metabolic syndrome comp

244 Adalimumab is indicated for the treatment of moderate to severe psoriasis in adults.

245 Use of systemic therapies for moderate to severe psoriasis in children is increasing,

246 se and relative risks of systemic agents for moderate to severe psoriasis in children.

247 , and included all consecutive children with moderate to severe psoriasis who used systemic medicatio

248 uited from specialty outpatient clinics with moderate to severe psoriasis without type 2 diabetes (re

249 nly used systemic drugs for the treatment of moderate to severe psoriasis; however, high-quality evid

250 Treatments used for moderate-to-severe psoriasis (phototherapy, oral systemi

251 receptor have proven efficacious in treating moderate-to-severe psoriasis, confirming IL-17 as an imp

252 s from the phase 3 studies of ustekinumab in moderate-to-severe psoriasis.

253 interleukin 17A in patients with widespread moderate-to-severe psoriasis.

254 of tofacitinib and etanercept in adults with moderate-to-severe psoriasis.

255 Moderate to severe pulse volume recording dampening was

256 Mean mood severity at screening was in the moderate to severe range.

257 your activity (ordinal scale 0-3)?" For CFS, moderate to severe reduction in daily activities had a p

258 Histology revealed moderate to severe rejection in allografts and no signs

259 male sex, history of diabetes mellitus, and moderate to severe residual aortic regurgitation were si

260 talization and 84% (95% CI, 64%-93%) against moderate to severe rotavirus.

261 tween older age and reduced risk for RVGE or moderate-to-severe RVGE given infection persisted after

262 Reminders via email were generated for all moderate to severe scores for symptoms and quality of li

263 adults (age +/- SD: 66.1 +/- 1.9 years) with moderate to severe SDB, defined as having an Apnea-Hypop

264 erial College London, of adult patients with moderate to severe seasonal allergic rhinitis (interferi

265 Recommendation 3: For treatment of moderate to severe seasonal allergic rhinitis in persons

266 Among patients with moderate to severe seasonal allergic rhinitis, 2 years o

267 Among patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism, the us

268 Among patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism, use of

269 in 1023 patients receiving hemodialysis with moderate to severe secondary hyperparathyroidism.

270 Eligible patients hospitalized with HF and moderate-to-severe sleep apnea were randomized to ASV pl

271 In hospitalized HF patients with moderate-to-severe sleep apnea, adding ASV to OMT did no

272 ar outcomes in hospitalized HF patients with moderate-to-severe sleep apnea.

273 es 2 and 3, more intense solar exposure, and moderate to severe solar lentigines; it was the most pre

274 2 diabetes) with diabetic gastroparesis with moderate to severe symptoms and delayed gastric emptying

275 symptom in the EMR for patients who reported moderate to severe symptoms on the ESQ.

276 However, many patients continue to have moderate-to-severe symptoms and are not satisfied solely

277 ergic children and adults to prevent further moderate-to-severe systemic sting reactions.

278 Moderate to severe TBI elicits neuroinflammation and c-J

279 o post-chiasmal lesions were associated with moderate to severe TBI or penetrating head injury, but o

280 of 32 children (23 males and 9 females) with moderate-to-severe TBI (msTBI) at 1-5 months postinjury,

281 discovered a divergence within our pediatric moderate-to-severe TBI sample 1-5 months postinjury.

282 e the prevalence of AF-TR, 437 patients with moderate to severe TR underwent 3-dimensional (3D) trans

283 years after individuals experience a single moderate to severe traumatic brain injury suggest widesp

284 Moderate-to-severe traumatic brain injury is one of the

285 cal and endoscopic outcomes of patients with moderate to severe ulcerative colitis receiving tofaciti

286 cal and endoscopic outcomes of patients with moderate to severe ulcerative colitis receiving tofaciti

287 y and safety of PF-00547659 in patients with moderate to severe ulcerative colitis.

288 for induction of remission in patients with moderate to severe ulcerative colitis.

289 phase 2 trial of ozanimod in 197 adults with moderate-to-severe ulcerative colitis.

290 ontrolled (PR, 1.33; 95% CI, 1.09-1.63), and moderate-to-severe uncontrolled asthma (PR, 1.37; 95% CI

291 ntrolled, moderate-to-severe controlled, and moderate-to-severe uncontrolled asthma.

292 the left renal vein 24 hours after inducing moderate-to-severe unilateral IRI in rats.

293 trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major

294 Clinical examination showed bilateral moderate to severe upper and lower tarsal conjunctival p

295 In the context of eyes with moderate to severe uveitis for years, this rate is not u

296 216.6 million (80% UI 98.5-359.1) people had moderate to severe visual impairment (2.95%, 80% UI 1.34

297 l acuity worse than 6/12 to 6/18 inclusive), moderate to severe visual impairment (presenting visual

298 Eight patients (21%) had moderate to severe visual impairment.

299 ey can be mild and restricted to the skin or moderate to severe with a risk of life-threatening anaph

300 th minimal WMH, Abeta-positive patients with moderate to severe WMH were significantly more likely to